A – Agilent Technologies, Inc.
Healthcare | Diagnostics & Research
Key Statistics
AI Monthly Analysis Report
Agilent Technologies, Inc. (A) – Monthly Stock Review (December 2025)
Publication Date: December 09, 2025
Company Overview
Agilent Technologies, Inc. (NYSE: A), headquartered in Santa Clara, California, operates within the Healthcare sector, specifically in the Diagnostics & Research industry. The company provides targeted solutions across life sciences, diagnostics, and applied chemical markets on a global scale. Agilent organizes its business into three primary segments: Life Sciences and Applied Markets, which offers various chromatography and mass spectrometry systems; Diagnostics and Genomics, which focuses on advanced biomolecular and cell analysis technologies; and Agilent CrossLab, delivering essential services like maintenance, training, and software support.
Agilent’s innovative position in the healthcare diagnostics market, coupled with its comprehensive product offerings and strategic focus, establishes the company as a key player within the sector. With a robust total revenue of approximately $6.95 billion in recent fiscal reports, Agilent has showcased a strong capability to adapt and thrive, making it an appealing investment opportunity.
52-Week Price Performance Analysis
52-Week Price Performance Chart
The stock performance of Agilent Technologies over the past year indicates noteworthy volatility, with a high of $160.27 and a low of $96.43. Presently, the stock trades at $143.61, slightly below its fifty-day moving average of $144.18(9), suggesting a mild downward trend relative to recent momentum.
The 52-week chart highlights a significant bullish trend emerging post-April, following an initial downtrend phase that saw prices dip towards $100. Starting in June, a strong recovery ensued, propelling the stock’s trajectory upward.
Key support and resistance levels emerge from this chart analysis:
– Support Level: $140 – Previously a resistance point, it was breached in October and has since transformed into a support level. Holding above this price will be crucial for upward movement.
– Resistance Level: $160 – The stock encountered selling pressure here in November, further establishing its role as a barrier to near-term price increases.
Momentum Analysis: The recent price crossover of the fifty-day moving average over the stock’s price in June indicates an established bullish momentum. Following a peak in November, recent trading has shown a pullback, testing the newly defined support at $140. This consolidation could set the stage for potential further upward movement, emphasizing a careful watch on price action around this level.
Financial Performance and Metrics
Agilent Technologies’ financial performance indicators are compelling:
– Total Revenue: Approximately $6.95 billion.
– EBITDA: $1.77 billion, indicating strong operational efficiency and profitability.
– Shares Outstanding: 283,054,377 shares, with 3,776,884 shares sold short, representing a short interest of 1.52%. This low percentage of short interest reflects general investor optimism.
In terms of valuation metrics, current price levels demonstrate favorable potential:
– Current Stock Price: $143.61
– Target High Price: $185.00
– Target Low Price: $151.00
– Mean Target Price: $169.40
– Median Target Price: $170.00
These metrics suggest a solid foundation for future price appreciation, positioning Agilent favorably against the backdrop of an overall positive outlook for the healthcare diagnostics market.
Recent News and Developments
Agilent Technologies has made recent headlines that continue to capture the market’s attention. A significant announcement on December 2, 2025, revealed a quarterly dividend of 25.5 cents per share, demonstrating the company’s commitment to returning value to shareholders. The dividend is set to be payable on January 28, 2026, for shareholders of record as of January 6, 2026[^1].
In terms of stock performance, Agilent shares have fluctuated, reaching a 52-week high of $153.85 on November 25, 2025, reflecting a 15.14% year-to-date increase despite a recent decline to $142.44 as of December 9, 2025, indicating a 2.06% drop from the prior close.
Analyst sentiment has shown dichotomy: On December 2, 2025, Morgan Stanley initiated coverage with an “Overweight” rating and a $180 price target, citing strong confidence in Agilent’s strategic initiatives[^2]. Conversely, BofA Securities reiterated a “Neutral” rating on July 15, 2025, with a $128 price target, following reminders of cautious expectations regarding Agilent’s fiscal performance[^3].
Market Sentiment and Analyst Recommendations
The overall market sentiment regarding Agilent Technologies remains positive, supported by a consensus of 15 analysts recommending a “buy.” The mean recommendation score has consistently hovered around 2.0, reflecting optimism about Agilent’s operational outlook and growth potential in the diagnostics sector.
Given Agilent’s current trading price of $143.61, analysts have set ambitious price targets:
– High Target: $185.00
– Mean Target: $169.40
– Median Target: $170.00
This suggests a strong upside opportunity, aligning with the overall upward trajectory anticipated in the diagnostics market. However, investors should remain aware of potential risks such as market volatility and underlying economic conditions that may affect stock performance moving forward.
Conclusion
In conclusion, Agilent Technologies, Inc. presents a compelling investment opportunity driven by robust financial performance, a significant market position, and recent analyst endorsements. The combination of solid dividends, a thriving operational structure, and an optimistic growth outlook facilitates a robust case for potential investors. Nevertheless, prudent investors should monitor the train tracks of price action, support levels, and overall market sentiment, considering both opportunities and risks in decision-making.
[^1]: Agilent Announces Cash Dividend of 25.5 Cents Per Share
[^2]: Morgan Stanley Initiates Coverage of Agilent with Overweight Rating
[^3]: BofA Securities Reiterates Neutral Rating on Agilent
| Metric | Value |
|---|---|
| Market Cap | $40.7b |
| Total Debt | $3.4b |
| Total Cash | $1.8b |
| Shares Outstanding | 283.1m |
| Float Shares | 282.1m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.
📅 Report Generated: Recently updated